SHSeyed Hamzeh Hosseini

Seyed Hamzeh Hosseini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Seyed Hamzeh Hosseini has a total of 284 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acute Olfactory Hypersensitivity to Opium and Cannabis Following Naltrexone Administration: A Rare Case Report

    by Seyed Hamzeh Hosseini, Raheleh Rafaiee

    Naltrexone, a long-acting opioid receptor antagonist, is commonly utilized to avert relapse in individuals with opioid or alcohol dependence. While its efficacy in modifying cue-reactivity and lowering desire is well documented, less is known regarding its ability to elicit negative sensory-emotional reactions, particularly in response to olfactory stimulation. We present a rare case of a 16-year-old male with a history of cannabis usage who experienced acute episodes of respiratory distress after starting oral naltrexone (50 mg/day). These episodes were consistently triggered by the smell of opium or cannabis smoke, despite the patient’s abstinence. The reactions were severe enough to necessitate multiple emergency medical procedures. The patient had a prior adverse reaction to morphine and a history of multiple drug allergies, suggesting a possible underlying sensitivity to opioid system modulation. The symptoms resolved after discontinuation of naltrexone. This case raises significant clinical and neurobiological concerns about the role of opioid antagonism in modifying olfactory and emotional processing. We propose that naltrexoneinduced disinhibition in olfactory-limbic circuits may have contributed to heightened sensory gain and conditioned unpleasant reactions in a sensitized individual. More research is needed to understand the mechanisms driving this unusual yet important reaction.

  • Open Access

    Initiation of Smoking After Electroconvulsive Therapy in a Non-Smoker Patient with Major Depression: A Case Report

    by Seyed Hamzeh Hosseini, Raheleh Rafaiee

    Electroconvulsive therapy (ECT) is a well-established intervention for treatment-resistant major depressive disorder (MDD). Although the neurobiological ramifications of ECT, particularly in relation to the mesolimbic dopaminergic system, have been correlated with the modulation of reward and reinforcement pathways, the capacity of ECT to influence substance-related behaviors remains inadequately elucidated. We report the case of a 42-year-old Iranian woman with a 14-year history of treatment-resistant MDD and no prior history of tobacco or other substance use. Following a second session of inpatient ECT, the patient experienced a sudden and intense craving for cigarettes, leading to the immediate initiation of daily smoking. This pattern of tobacco use persisted for several years, despite multiple motivated attempts at cessation. The patient’s psychiatric management included standard pharmacotherapy and supportive interventions, but ongoing nicotine dependence remained challenging. There was no personal or family history of substance use, and no exposure to smoking in the inpatient setting, aside from a shared room with a smoker in a different ward. To our knowledge, this is the first documented case of cigarette smoking initiation following ECT in a non-smoking patient with MDD. The case underscores the need for heightened clinical vigilance and further investigation into ECT’s effects on addictive vulnerability and reward processing.

  • Acute Urinary Retention Associated with Trazodone: A Case Report

    by Seyed Hamzeh Hosseini, Hamed Ghazvini, Seyedeh Masoumeh Seyedhosseini Tamijani, Raheleh Rafaiee

    Introduction: Trazodone is an antidepressant that acts on multiple serotonin receptors, particularly 5‑HT2A and 5‑HT2C, contributing to its antidepressant and anxiolytic effects. While most urinary side effects linked to trazodone involve incontinence, acute urinary retention is rarely reported. Pharmacological effects on serotonin receptors and possible anticholinergic‑like activity may influence urinary function. Case Report: We presented a 41‑year‑old woman treated with trazodone for depression and claustrophobia, who developed severe acute urinary retention lasting three days. The patient experienced difficulty initiating urination, with no prior urinary tract pathology. After discontinuation of trazodone, spontaneous urination resumed promptly and without recurrence. Conclusion: Although acute urinary retention is an uncommon adverse effect of trazodone, clinicians should remain vigilant, particularly in patients with risk factors for impaired bladder emptying. Careful monitoring of urinary function may help prevent complications while ensuring effective treatment of psychiatric conditions.

  • Open Access

    Unexpected Improvement of Obsessive–Compulsive Disorder Symptoms Following the Mistaken Prescription of Clomiphene: A Novel Perspective on Hormonal Influences in OCD

    by Seyed Hamzeh Hosseini, Behnam Abbasi, Fatemeh Abedian Kenari

    Background: Obsessive–compulsive disorder (OCD) is a chronic psychiatric disorder commonly treated with selective serotonin reuptake inhibitors (SSRIs) and, in more severe or resistant cases, clomipramine. Clomiphene citrate, a selective estrogen receptor (ER) modulator primarily used for infertility, is not indicated for psychiatric disorders but may influence neuroendocrine and serotonergic pathways. This case describes an unexpected improvement in OCD symptoms following the accidental prescription of clomiphene instead of clomipramine. Case Presentation: A 50‐year‐old woman with a longstanding history of anxiety and recurrent major depressive disorder (MDD) developed OCD symptoms after childbirth during her second pregnancy. Her symptoms previously responded well to sertraline, clonazepam, and clomipramine. After ~15 years of relative stability, clomipramine was discontinued because of anticholinergic side effects, resulting in relapse of obsessive–compulsive symptoms. A 3‐month trial of sertraline 200 mg/day was ineffective. When clomipramine was intended to be restarted, a prescribing error led to clomiphene 25 mg/day being dispensed instead. The patient took clomiphene together with sertraline 100 mg/day and clonazepam 2 mg/night for 12 weeks. During this period, she experienced a dramatic and complete remission of her obsessive–compulsive symptoms, with an estimated reduction in Yale‐Brown Obsessive Compulsive Scale (Y‐BOCS) score from 23 to ~7. No adverse effects were identified. After the error was recognized, clomiphene was discontinued, the incident was reported, and clomipramine was reintroduced, although the same degree of improvement was not reproduced. Conclusion: This case raises a speculative but clinically important hypothesis regarding the possible role of hormonal modulation in a subgroup of hormonally sensitive patients with OCD. However, causality cannot be established because hormonal measurements were unavailable and alternative explanations, including placebo effects, spontaneous symptom fluctuation, and concomitant medication effects, remain possible. Future studies should longitudinally assess OCD symptom changes during hormonally sensitive periods, ideally in conjunction with standardized clinical measures and hormonal biomarkers. The case also underscores the ethical and patient‐safety importance of preventing medication errors.

  • A high-power near-infrared photobiomodulation device: design, fabrication, and primary impact on treatment-resistant depression

    by Seyed Hamzeh Hosseini, Seyed Alireza Zamani, Yasser Baleghi, Hossain Ahmadi Noubar, Maryam Rezapour, Maryam Hasannezhad Reskati

    Depression is a prevalent psychiatric disorder, affecting a significant portion of the population. However, approximately 30% of patients do not respond adequately to conventional treatments and develop treatment-resistant depression. Despite notable advancements in psychiatry, effectively treating individuals with treatment-resistant depression remains a significant challenge. Photobiomodulation represents an emerging therapeutic approach for depression, utilizing an enhanced near-infrared therapy device. The objective of this study was to evaluate the primary effects of the usage of high-power enhanced near-infrared therapy device on patients suffering from treatment-resistant depression. In this open-label, four-week study, seven right-handed patients categorized as treatment-resistant depression were recruited. Each participant received a daily 2 min intervention (continuous wave; 850 nm peak wavelength; average irradiance of 127 mW/cm²; average fluence per pulse of 6.35 mJ/cm²; total energy delivered per session of 0.3 kJ; output optical power set to 5000 milliwatts; electromagnetic waves set to 10 Hz). Depression severity was assessed using the Hamilton Depression Rating Scale (HAM-D) before and four weeks after the completion of the intervention. During the treatment, each patient underwent eight treatment sessions, each lasting 2 min: first, the device was applied to the left frontal (F3) area, near the left prefrontal cortex, and then, to the right frontal area (F4) on the forehead. Notably, the depression scores showed a significant reduction after four weeks of treatment. The median HAM-D score decreased from 23 before the intervention to 9 after four weeks, while the mean HAM-D score declined from 28.14 (P = 0.18) to 8.71 (P = 0.09) post-intervention. This preliminary study suggests that the high-power enhanced near-infrared therapy device holds promise in reducing depression among patients suffering from treatment-resistant depression.

  • Urinary Incontinence During Sleep Associated With Buspirone: A Case Report

    by Seyed Hamzeh Hosseini, Hamed Ghazvini, Seyedeh Masoumeh Seyedhosseini Tamijani, Raheleh Rafaiee

  • Open Access

    The Psychometric Properties of the Post‐Traumatic Stress Disorder Questionnaire (PCL‐5) for Cancer Patients in Iran

    by Maryam Hasannezhad Reskati, Hamid Sharif‐Nia, Seyed Hamzeh Hosseini, Hossein Azadeh, Behnoush Yazdirad, Reza Alizadeh‐Navaei, Forouzan Elyasi

    Background: Cancer is known as a common chronic disease that many aspects of its diagnosis and treatment may manifest traumatic episodes and lead to the post‐traumatic stress disorder (PTSD) associated with cancer. Avoidance symptoms in PTSD often delay individuals from seeking professional assistance. Therefore, the PTSD Checklist for the Diagnostic and Statistical Manual of Mental Disorders‐5th Edition or DSM‐5 (PCL‐5) can evaluate PTSD conceptually and psychometrically instead of avoidance responses.Aims: Accordingly, this research aimed to explore the psychometric features of the PCL‐5 Persian version in the population of gastrointestinal cancer patients in Iran.Methods: As the instrument of the research, the Persian version of PCL‐5 was conducted on 486 gastrointestinal cancer patients who referred to Baghban Clinic, the cancer research center of “REDACTED” University of Medical Sciences, and Imam Khomeini Hospital in Sari from July 2021 to May 2022. The used questionnaire survey included two sections. The first part consisted of questions regarding participants' profiles, such as age, gender, and job status. In the second section, the Posttraumatic Stress Disorder item 20 was used to measure (PCL‐5) Participants were asked to respond to each statement with a 5‐point range Likert scale from 0 to 4.Results: Exploratory factor analysis showed four‐factor structures for PCL‐5, explaining 43.17% of the total variance. According to the mentioned analysis, each fit index verified the model fit. All internal consistency coefficients were also predicted to be acceptable reliability. It can be concluded from the data that highlighted good psychometric features for PCL‐5, suggesting the effectiveness of this scale for the screening of PTSD in gastrointestinal cancer patients.Conclusion: This study indicates the effectiveness and usefulness of the Persian version of the PCL‐5 scale for assessing post‐traumatic stress in the cases suffering from gastrointestinal cancer.


  • Open Access

    tDCS Targeting the DLPFC for Reducing Cigarette Craving and Risky Decision Making

    by Saba Niknamfar, Kamaledin Alaedini, Azarakhsh Mokri, Eisa Nazar, Raheleh Rafaiee, Seyedeh Masoumeh Seyedhosseini Tamijani, Seyed Hamzeh Hosseini, Hamed Ghazvini

    Introduction: Cigarette smoking is a prevalent addictive behavior. Despite its well-known health risks, many individuals are unable to quit. One of the key factors contributing to the failure of smoking cessation efforts is the presence of craving and the tendency toward risk-taking behaviors. Noninvasive brain stimulation techniques have recently emerged as ...

  • Open Access

    Childhood trauma and Axis I disorders in borderline personality disorder: a correlational study

    by Sabahat Lavvaf, Masoumeh Bagheri-Nesami, Mahdieh Nasiri, Seyed Hamzeh Hosseini

    Background: Axis 1 disorders often occur in combination with borderline personality disorders (BPD), which complicates treatment and diagnosis. Also, childhood trauma is found to be an underlying factor in patients with BPD. Considering the various statistics and the importance of accompaniment, this study aims to determine the prevalence of Axis 1 disorders in BPD and evaluate the association with childhood trauma. Materials and methods: In this descriptive-analytical study, 239 patients with BPD were examined among patients referred to the psychiatric hospital in Sari, North of Iran. To confirm the diagnosis, the semi-structured clinical interview for DSM-IV (SCID-1) was performed, and the history of childhood trauma was assessed with the Early Trauma Inventory-Self Report. Data after collection was entered into SPSS software and using descriptive statistics like absolute and relative abundance. Mean and standard deviation and inferential statistics were analyzed. Results: The prevalence of major depressive disorder (MDD) was 59.8%, obsessive–compulsive disorder (OCD) 53.1%, generalized anxiety disorder (GAD) 17.6%, and phobias 23.4% in BPD. There was also a significant association between childhood emotional trauma and MDD (P = 0.03) and substance use disorder (SUD, P = 0.008), neglect trauma with post-traumatic stress disorder (PTSD, P = 0.03), phobia (P = 0.001) and GAD (P = 0.02), and physical and sexual trauma with SUD (P = 0.02). Conclusion: Axis 1 disorders are common in patients with BPD. Childhood trauma with its effects on the brain of children and adolescents can lead to chronic disabilities in coping with arousal fluctuations and consequently to increased emotional disturbances including BPD and depression, which in turn leads to self-injurious behavior.